Sep 2, 2016 - THE WELLCOME FOUNDATION. LTD. GR. Valtrex 250 mg comprimidos revestidos por pelÃcula. SE/H/1041/001. 2966083. LABORATORIOS WELLCOME DE. PORTUGAL LIMITADA. PT. Valtrex 250 mg comprimidos revestidos por pelÃcula. SE/H/1041/001. 3131786.
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Oct 29, 2016 - should be discontinued if there is persistent bleeding and no alternative explanations are identified. Package Leaflet. 2. Warnings and precautions. Cefoperazone - active substance of â may inhibit blood clotting. Serious bleedings,
Jan 28, 2017 - The primary analysis examined sudden death within seven days of an outpatient prescription for one of ... Package Leaflet. â¢. Section 2.
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Oct 29, 2016 - Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through). Summary of Product Characteristics. â¢. Section 4.6. Prolonged use of hydromorphone during p
the EU have access to high-quality, effective and safe medicines. The centralised ... Pharmaceutical companies submit a single authorisation application to EMA. .... guide the development programmes of all medicine developers who wish to ...
Mar 11, 2017 - Considering the presented cumulative analysis of cases reporting withdrawal symptoms and drug abuse the ... Package Leaflet. â¢. Section 4 ...
Sep 20, 2016 - (R6) What kinds of safety data are required for applications ..... has to be demonstrated by using appropriate analytical data, for example.
